Home › Companies › MDNAF

Medicenna Therapeutics

Market cap $14.8M 92.3M shares (vendor count, Nov 18, 2026) × $0.160 close Nov 17, 2026 · share count from the market-data vendor, not the SEC cover page

Most recent annual filing: 2023-06-27

Catalyst timeline

3 trackedQuarter catalyst calendar →
  1. MDNA11 interim2H 2026MDNA11 interim, 2H 2026, material
  2. MDNA11 FDA feedback2H 2026MDNA11 FDA feedback, 2H 2026, notable
  3. MDNA113 IND filing2027MDNA113 IND filing, 2027, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (10 active programs)

Technology platforms

BiSKITs

Bi-functional SuperKine ImmunoTherapies platform that fuses IL-2, IL-4, and/or IL-13 Superkines with proteins, antibodies, checkpoint inhibitors, or other Superkines to create dual-function molecules for treatment of cancers, including immunologically cold tumors

Targets: IL-2Rβ, PD-1, IL-4R, IL-13Rα2, IL-2

T-MASK

Targeted Metalloprotease Activated SuperKine platform — conditionally activates IL-2 Superkine payloads via tumor-associated MMP cleavage and proximity-dependent unmasking in the tumor microenvironment; focus on solid tumors

Targets: MMP, IL-13Rα2, PD-1, IL-2, CD122, IL-15

BiSKIT

Bifunctional Superkine immunotherapy platform used to develop targeted cytokine fusion candidates, including PD-1 x IL-2 bifunctional immunotherapies for solid tumors

Targets: PD-1, IL-2

Capital (as filed)

Cash
C$33.6M cash and cash equivalents · Mar 31, 2023 (20-F) · more than a year old
Operating cash flow
−C$12.7M quarter to Mar 31, 2023 (20-F)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (12)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (12 calls)

Every verdict Biotech Distilled has published on Medicenna Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Medicenna Therapeutics (MDNAF) - Scientific Deep Dive for MDNA11 and Pipeline Products Elegant protein engineering and real clinical responses, but dire balance sheet and Q3 2026 cash cliff make buying premature until dilution risk is cleared via a bizaxofusp partnership or capital raise.
  2. Watch UPDATE: Medicenna Therapeutics (MDNAF) - The Science Wins, the Cash Cliff Looms Closer MDNA113 AACR data validated the architecture thesis and CMO hire adds M&A credibility, but no partnership materialized and the cash clock is now one quarter away, keeping the setup binary and watch-only.
  3. Avoid UPDATE: Medicenna Therapeutics (MDNAF) - The Dilution Headline Lands The bear-case dilutive raise has arrived with no accompanying partnership; stepping in front of a marketed offering before the price prints is bad math given float expansion and likely warrant overhang.
  4. Watch UPDATE: Medicenna Therapeutics (MDNAF) - The Pricing Print Lands, and the Tape Tells You Everything Offering terms are now in the tape with confirmed warrant overhang, but the Prospectus Supplement with actual price, size, and warrant terms must be read before sizing any position.
  5. Speculative buy speculative UPDATE: Medicenna Therapeutics (MDNAF) - The Prospectus Supplement Drops, and a Sorbie Wrinkle Appears The Sorbie Bornholm 16M-unit anchor plus a non-dilutive Sharing Agreement kicker makes the structure more creative than a standard discounted raise, partially satisfying the non-dilutive bridge condition that was the original buy trigger.
  6. Speculative buy speculative UPDATE: Medicenna Therapeutics (MDNAF) - The Marketed Tranche Closes at CDN$4.44M, Sorbie Still Pending Marketed tranche cleared the binary tripwire but came in at the floor of the range; Sorbie close remains the swing factor between a real multi-quarter bridge and a months-long partial one.
  7. Speculative buy speculative UPDATE: Medicenna Therapeutics (MDNAF) - FY2026 Results, a "Fractional" CMO, and the Sorbie Clock Science thesis reaffirmed with Q4 2026 catalyst calendar now sharper, but Sorbie still unconfirmed five weeks on and the CMO disclosed as fractional dilutes the Merck-deal tea-leaf read.
  8. Speculative buy speculative UPDATE: Medicenna Therapeutics (MDNAF) - Two Oral Slots, One Slipped IND, and Sorbie Still in Forward-Looking Tense Two oral presentation slots for lead assets at Q4 conferences sharpen the partner-facing catalyst stack, but MDNA113 IND slipped to 2027, Sorbie remains unconfirmed twelve weeks on, and the financing window and data window are uncomfortably close.
  9. Hold UPDATE: Medicenna Therapeutics (MDNAF) - The Reverse Split Gets a Green Light Reverse-split authorization signals a likely U.S. listing and raise is coming; downgraded from Speculative Buy as the risk of another raise before the Q4 data stack has moved from abstract to visible, but not yet AVOID since no ratio or offering has been announced.
  10. Hold UPDATE: Medicenna Therapeutics (MDNAF) - The First Q4 Oral Lands: 40% at SITC, With an Asterisk MDNA11 posts a credible 31% ICI-refractory GI response rate at SITC with a named registrational indication, but confirmed ORR is 25%, Sorbie remains unconfirmed, and two of three Q4 events still pending.
  11. Hold UPDATE: Medicenna Therapeutics (MDNAF) - Bizaxofusp Doubles Survival at SNO, on Borrowed Controls Bizaxofusp delivers strongest-ever clinical package with FDA-endorsed Phase 3 design at SNO, but financing remains unresolved with Sorbie unconfirmed, conditional runway nearly expired, and a 17.5% weekly slide into two positive orals signals the market is pricing the cap table.
  12. Avoid UPDATE: Medicenna Therapeutics (MDNAF) - The Cash Line Arrives $3.7M cash with an explicit twelve-month going-concern warning, vanished Sorbie mention, lost runway guidance, and undated NEO-CYT readout signal a forced raise is imminent at distressed pricing before remaining catalysts can land.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (20)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Apr 30, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

1 more filing (13G holder notices, S-8, proxy material, SEC correspondence …)